{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Nguyen MH"],"funding":["Cystic Fibrosis Foundation","Bundesamt für Gesundheit"],"pagination":["106103"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12804157"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["123"],"pubmed_abstract":["<h4>Background</h4>Current treatment regimens for nontuberculous mycobacteria (NTM) infections, especially Mycobacterium abscessus, have suboptimal clinical outcomes, demanding novel therapeutic options. The aminoglycoside apramycin (APR) has been suggested as a therapeutic alternative to amikacin (AMK). Here, we report experimental data as part of an ongoing preclinical assessment of APR.<h4>Methods</h4>Antimicrobial activity against 828 isolates comprising the clinically most relevant NTM species were determined by broth microdilution. Bactericidal activity and killing kinetics of APR were determined across a variety of assay conditions against rough and smooth M. abscessus isolates in vitro and in vivo.<h4>Findings</h4>Both the MIC<sub>90</sub> and tentative epidemiological cutoff (TECO"],"journal":["EBioMedicine"],"pubmed_title":["Multicentre preclinical profiling of apramycin for the treatment of nontuberculous mycobacteria."],"pmcid":["PMC12804157"],"funding_grant_id":["JUVABIS22W0","HOBBIE19I0"],"pubmed_authors":["Krishnamurthy RV","Haldimann K","Plattner M","Becker K","Narayanan S","Xie M","Kaur P","Bulman ZP","Hobbie SN","Shandil RK","Calado Nogueira de Moura V","Verma D","Schulthess B","Singh M","Daley CL","Mitarai S","Lang R","Nguyen MH","Dick T"],"additional_accession":[]},"is_claimable":false,"name":"Multicentre preclinical profiling of apramycin for the treatment of nontuberculous mycobacteria.","description":"<h4>Background</h4>Current treatment regimens for nontuberculous mycobacteria (NTM) infections, especially Mycobacterium abscessus, have suboptimal clinical outcomes, demanding novel therapeutic options. The aminoglycoside apramycin (APR) has been suggested as a therapeutic alternative to amikacin (AMK). Here, we report experimental data as part of an ongoing preclinical assessment of APR.<h4>Methods</h4>Antimicrobial activity against 828 isolates comprising the clinically most relevant NTM species were determined by broth microdilution. Bactericidal activity and killing kinetics of APR were determined across a variety of assay conditions against rough and smooth M. abscessus isolates in vitro and in vivo.<h4>Findings</h4>Both the MIC<sub>90</sub> and tentative epidemiological cutoff (TECO","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Jan","modification":"2026-06-06T16:07:51.392Z","creation":"2026-06-02T03:11:14.511Z"},"accession":"S-EPMC12804157","cross_references":{"pubmed":["41478260"],"doi":["10.1016/j.ebiom.2025.106103"]}}